Candel Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully secured $80 million in funding to advance its innovative approach to cancer treatment. Candel, traded under the ticker symbol $CADL, is focused on developing off-the-shelf multimodal biological immunotherapies designed to provoke a robust and personalized anti-tumor immune response for patients battling various forms of cancer. This significant investment will play a critical role in the progression of Candel’s leading product candidates, particularly CAN-3110, which is currently being examined in a phase 1 clinical trial targeting recurrent high-grade glioma (HGG). Additionally, the funding will bolster ongoing trials of CAN-2409, developed from Candel’s adenovirus platform, which is being evaluated in pivotal phase 2 and phase 3 studies for non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized non-metastatic prostate cancer. Candel’s cutting-edge enLIGHTEN™ Discovery Platform will also benefit from this financial boost, allowing the company to leverage human biology and advanced analytics in the creation of new viral immunotherapies for solid tumors. As the battle against cancer continues to evolve, Candel Therapeutics is at the forefront of developing transformative therapies that offer hope and improved outcomes for patients around the world. For more detailed information about the company’s initiatives and ongoing programs, visit www.candeltx.com or reach out via email at info@candeltx.com.
Candel Therapeutics Secures $80 Million in Funding to Advance Cancer Immunotherapy Platforms
Recently funded · $80.0MHealthcare
Get the full Candel Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
